Articles By Ed Miseta

61. Sparrow Pharmaceuticals Hopes To Change The Future Of Endocrinology 11/2/2021

    Sparrow Pharmaceuticals is an emerging biopharma company on a mission to help patients suffering from an excess of corticosteroids, with a focus on Cushing’s syndrome, ACS, and PMR. The treatments being developed are based on recognition that cortisol and corticosteroid medications are activated in certain tissues such as the liver, bone, fat, and brain, where in excess they act to cause toxicity.

62. How Real-World Data Will Advance Oncology Clinical Trials 10/28/2021

    Real-world data (RWD) is coming to fruition in clinical trials. One area where it is expected to have a huge impact on innovation is oncology studies. This topic was discussed by a panel of experts at The Future of Health Data conference hosted by Datavant.

63. Data Liquidity: Privacy, Ethics, And Patient Benefit 10/26/2021

    There has been a push in recent years to increase the liquidity of patient data and make that data more accessible to the patients from whom it was gathered. But increasing the liquidity of data also increases concerns around privacy and ethics.

64. From Fusion Energy To Med Device … To Drug Developer? 10/21/2021

    It’s not often you hear the CEO of a life sciences company say things like, “The big technology advancement we were waiting on was using accelerators to generate the needed neutron radiation.” Of course, not many life sciences companies have “fusion energy” listed as one of their areas of expertise. But that’s not the only thing atypical about TAE Life Sciences (TLS).

65. Why Has There Been A Shift In Power In Pharma Partnering? 10/19/2021

    When it comes to partnering models in drug development, Syed Kazmi, CEO of Jubilant Therapeutics, believes there has been a dramatic shift in the thinking of pharma companies. Kazmi has worked for both pharma and biotech companies and on both the business and R&D sides of the house. That gives him a unique perspective on and appreciation for how partnering has evolved.

66. Dispelling The Misconceptions Of Conducting Clinical Trials In Russia 10/8/2021

    Russia is a growing area for clinical trials. In 2018, 654 new trials were approved in Russia. Approximately 50% of those trials were initiated by multinational companies led by Novartis, Roche, Pfizer, Janssen, Abbvie, AstraZeneca, and Merck. Oncology trials led the way with 114 trials, followed by rheumatology and neurology.

67. Decentralized Trials Can Overcome The Challenges Of Rare Disease Patients 10/5/2021

    There are 400 million people worldwide who are impacted by more than 7,000 identifiable rare diseases. While individual rare diseases are uncommon, approximately 5% of the world’s population suffers from one. A new report from technology provider THREAD details how many of the clinical challenges posed by rare disease trials can be alleviated by decentralized trials.

68. Seagen Leverages Partnerships to Understand Patient Perspectives 9/30/2021

    Patient recruitment, retention, and diversity in clinical trials has been an ongoing challenge. While there is an industry-wide effort underway to try and address these issues, they will not be truly impacted until researchers are able to create a better patient experience, do a better job of reaching patients from diverse communities, building true relationships, and working to co-create solutions as equal partners.

69. Janssen's Personalized Approach To Depressive Disorder Patients 9/28/2021

    Janssen is currently developing new treatments for patients with depressive disorders. The company is focused on patients with treatment resistant depression (TRD), or patients who did not have success with existing drugs. To help those patients, the company opted to take a personalized approach to the treatments.

70. Five Issues That Must Be Addressed To Advance The Use Of RWE 9/21/2021

    Edith Perez, CMO for Bolt Biotherapeutics, believes the industry has historically struggled to deliver on the promise of RWE. She notes there are five issues that still exist around the gathering and use of real-world data (RWD) that the industry will need to overcome.